SynthesisPloS one2025
The safety and feasibility of transoral thyroidectomy vestibular approach in the treatment of thyroid disorders: An overview of systematic reviews.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMany systematic reviews (SRs) and meta-analyses (MAs) have recently assessed the short-term outcomes of the transoral thyroidectomy vestibular approach (TOTVA) compared with conventional open thyroidectomy (COT) and non-transoral endoscopic thyroidectomy (NTET). However, their conclusions remain controversial. This overview aimed to evaluate the safety and feasibility of TOTVA by appraising the quality of existing SRs/MAs.
methodsSeven Chinese and English databases were systematically searched from their inception to December 10, 2023. Eligible SRs/MAs, published between 2020 and 2023, compared the safety and efficacy of TOTVA with COT or NTET. The PRISMA, AMSTAR-2, and ROBIS tools were used to assess reporting quality, methodological quality, and risk of bias, respectively.
resultEleven SRs/MAs were finally included. According AMSTAR-2, one study was assessed as high-quality, with the remainder as very low-quality. Using PRISMA 2020, the "Yes" response rate for Q5, Q8, and Q15 was below 55 percent. Per ROBIS, all SRs/MAs exhibited low risk in phase 1 and domain 1 but high risk in domain 2. Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.
conclusionThe TOTVA may enhance cosmetic satisfaction, improve lymph node retrieval, and decreased postoperative complications. Nevertheless, these findings warrant cautious interpretation due to low methodological quality, high risk of bias, and limited evidence quality. More rigorous and standardized SRs/MAs are required to provide robust scientific evidence for definitive conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.